ISSN:
1573-7241
Keywords:
angiotensin-converting enzyme inhibitors
;
left ventricular dysfunction
;
myocardial infarction
;
myocardial remodeling
;
unstable angina
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Angiotensin-converting enzyme (ACE) inhibitor therapy has been associated with a substantial (≥20%) reduction in the risk of major ischemic events in two recent clinical trials with long-term follow-up: Studies of Left Ventricular Dysfunction (SOLVD) and the Survival and Ventricular Enlargement (SAVE) study. Participants in these studies included patients with a low ejection fraction (≤0.35 in SOLVD and ≤0.40 in SAVE), generally without symptoms of congestive heart failure. Approximately 80% of patients enrolled in SOLVD and all participants in SAVE had histories of ischemic heart disease or acute myocardial infarction (SAVE). In both SOLVD and SAVE the risk of experiencing a major ischemic event such as myocardial infarction was reduced significantly following prolonged ACE inhibitor therapy. In the SOLVD trial, this effect was evident across a range of patient subgroups, including varying concomitant drug therapies. In both studies, several months elapsed before this benefit became apparent, suggesting an effect on underlying ischemic pathophysiology. A third trial of ACE inhibitor therapy postinfarction, the Acute Infarction Ramipril Efficacy (AIRE) Study, demonstrated a 27% reduction in all cause mortality but no effect on myocardial infarction after a 15-month mean follow-up. No effect of ACE inhibition on risk of survival or reinfarction was reported in the Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS-II), which began the drug within 24 hours of infarction and terminated follow-up at 6 months, a time not likely to demonstrate infarction reduction benefit based on the SOLVD and SAVE observations. Neither AIRE nor CONSENSUS-II had objectively determined left ventricular dysfunction as an entry criterion, as did SOLVD and SAVE, but AIRE mandated “clinical” congestive heart failure prior to randomization. More recently, preliminary results from the third Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3), the Fourth International Study of Infarct Survival (ISIS-4), and the Chinese Captopril Trial suggested that angiotensin-converting enzyme (ACE) inhibitor mortality benefits post-myocardial infarction would be detected in these megatrials as early as 35 days after the event. The mechanism of ACE inhibitor benefit is likely multifactorial and linked to a variety of cardiac and vascular protective mechanisms currently being elucidated. Additional trials are required to ascertain if ACE inhibitors might effect similar benefits in other high-risk populations, such as patients with hypertension or diabetes alone, and to determine if this is a drug class effect or is specific to individual medications studied.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00877749
Permalink
